Abstract
Background/Aim: The occurrence of BRAFV600E mutation causes an up-regulation of the B-raf kinase activity leading to the stabilization of hypoxia-inducible factor 1-alpha (HIF-1α) - the promoter of the 6-phosphofructo-2- kinase/fructose-2,6-biphosphatase 3 (PFKFB3) enzyme. The aim of the study was to examine the effect of the (2E)-3-(3- Pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO), as an inhibitor of PFKFB3, on human melanoma cells (A375) with endogenous BRAFV600E mutation. Materials and Methods: A375 cells were exposed to different concentrations of 3PO and the following tests were performed: Docking, cytotoxicity assay, immunocytochemistry staining glucose uptake, clonogenic assay, holotomography imaging, and flow cytometry. Results: Our studies revealed that 3PO presents a dose-dependent and time-independent cytotoxic effect and promotes apoptosis of A375 cells. Furthermore, the obtained data indicate that 3PO induces cell cycle arrest in G1/0 and glucose uptake reduction. Conclusion: Taking all together, our research demonstrated a here should be proapoptotic and antiproliferative effect of 3PO on A375 human melanoma cells.
Cite
CITATION STYLE
Kotowski, K., Supplitt, S., Wiczew, D., Przystupski, D., Bartosik, W., Saczko, J., … Kulbacka, J. (2020). 3PO as a selective inhibitor of 6-phosphofructo- 2-kinase/fructose-2,6-biphosphatase 3 in a375 human melanoma cells. Anticancer Research, 40(5), 2613–2625. https://doi.org/10.21873/anticanres.14232
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.